CLL/SLL patients

We Need Your Help!

Lymphoma Canada is preparing a submission for Canada’s Drug Agency (CDA) and to INESSS (Institut national d’excellence en santé et en services sociaux), the Quebec equivalent. This survey provides us with the patient input required for the submission. CDA uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.

The drug that will soon be reviewed by CDA/INESSS is Acalabrutinib, a BTK inhibitor, in combination with venetoclax, a BCL-2 inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia.

You do not need to live in Canada to complete this survey. You can still participate in this survey if you are a CLL/SLL patient who has not received this therapy.

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

It should only take between 15-20 minutes of your time.

Please share and help us spread the word.

TAKE SURVEY